# A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther

Source: https://onco.cc/trials/nct07796100/  
OnCo record `nct07796100` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of carboplatin and lurbinectedin in lung cancer, run by Zai Lab (Shanghai) Co., Ltd., not yet recruiting.

## Summary

A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07796100 by Zai Lab (Shanghai) Co., Ltd., with a registry enrolment figure of 530 participants, started 2026-12-31 and due to reach its primary completion in 2030-06-30. Interventions recorded: ZL-1310 in combination with Atezolizumab or Durvalumab; Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin; Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance. Conditions listed: Extensive-Stage Small Cell Lung Cancer. Primary outcome: Overall survival of ZL-1310 with IO compared to chemo with IO. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed ES-SCLC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07796100
- Phase: 3
- Setting: A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-drug Conjugate (ADC) in Combination With a Checkpoint Inhibitor Compared to Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer
- Sponsor: Zai Lab (Shanghai) Co., Ltd.
- Enrolled: 530

## Sources

- ClinicalTrials.gov NCT07796100: https://clinicaltrials.gov/study/NCT07796100

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/)
- companies: [Zai Lab](https://onco.cc/companies/zai-lab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07796100.json